SCHEMBL2383675

SCHEMBL2383675

CCOC(=O)N1Cc2sccc2C(Cl)=C1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PRKCZ Q05513 1/20 0.36
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36
NOS2 P35228 1/20 0.36
PKM P14618 2/20 0.35
MAPT P10636 5/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
ALDH1A1 P00352 2/20 0.34
POLB P06746 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPSR1 Q6W5P4 2/20 0.34
BRD4 O60885 1/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1936874 0.87 ABCB11 (0.34) SMN1; SMN2MAPTALDH1A1POLBCYP2C19
SCHEMBL16136745 0.82 GSK3B (0.33)
SCHEMBL2381115 0.75 THRB (0.32) HSD17B10SMN1; SMN2PKMMAPTMAPK1
SCHEMBL4751608 0.72 MAPT (0.44) HSD17B10SMN1; SMN2NOS3NOS1NOS2
SCHEMBL1425864 0.69 KDM4E (0.46) HSD17B10SMN1; SMN2NOS3NOS1NOS2
SCHEMBL985894 0.67 NOS3 (0.44) HSD17B10SMN1; SMN2NOS3NOS1NOS2
SCHEMBL1182615 0.66 SMN1; SMN2 (0.42) HSD17B10SMN1; SMN2NOS3NOS1NOS2
SCHEMBL2994625 0.64 ALDH1A1 (0.41) HSD17B10SMN1; SMN2NOS3NOS1NOS2
SCHEMBL2994626 0.64 ALDH1A1 (0.41) HSD17B10SMN1; SMN2NOS3NOS1NOS2
SCHEMBL12563513 0.64 ALDH1A1 (0.41) HSD17B10SMN1; SMN2NOS3NOS1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2539345-A1 4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO]THIENO [2, 3 - D]PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS Boehringer Ingelheim International GmbH (DE) 2013-01-02 EP disclosed
US-20110217311-A1 CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-09-08 US disclosed
WO-2011104334-A1 4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO] THIENO [2, 3 - D] PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110217311-A1 CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DTYMK, CMPK1, UCK2 HSD17B10 2507/4885SMN1; SMN2 576/4885PRKCZ 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.